Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth

Cancer Research

Volumn 65, Issue 21, 2005, Pages 9779-9788

  Sartorius, Carol A ^a   Harvell, Djuana M E ^a   Shen, Tianjie ^a   Horwitz, Kathryn B ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 8; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; MEDROXYPROGESTERONE ACETATE; MITOGENIC AGENT; PLACEBO; PROGESTERONE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER INCIDENCE; CANCER MODEL; CELL DIFFERENTIATION; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ESTROGEN ACTIVITY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HORMONE ACTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MOUSE; MYOEPITHELIUM CELL; NONHUMAN; NUDE MOUSE; PHENOTYPE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROGNOSIS; PROTEIN EXPRESSION; TARGET CELL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; FEMALE; HUMANS; KERATINS; MEDROXYPROGESTERONE 17-ACETATE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROGESTERONE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRANSPLANTATION, HETEROLOGOUS;

EID: 27544495512     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0505     Document Type: Article

References (50)

1. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev 1997;18: 502-19.
2. Matthews J, Gustafsson JA. Estrogen signaling: a subtle balance between ERα and ERβ. Mol Interv 2003; 3:281-92.
3. Hewitt SC, Korach KS. Oestrogen receptor knockout mice: roles for oestrogen receptors-α and -β in reproductive tissues. Reproduction 2003;125:143-9.
4. Conneely OM, Mulac-Jericevic B, Lydon JP, De Mayo FJ. Reproductive functions of the progesterone receptor isoforms: lessons from knock-out mice. Mol Cell Endocrinol 2001;179:97-103.
5. Cho H, Aronica SM, Katzenellenbogen BS. Regulation of progesterone receptor gene expression in MCF-7 breast cancer cells: a comparison of the effects of cyclic adenosine 3′,5′-monophosphate, estradiol, insulin-like growth factor-I, serum factors. Endocrinology 1994;134: 658-64.
6. Southcott BM. Carcinoma of the endometrium. Drugs 2001;61:1395-405.
7. Soderqvist G. Effects of sex steroids on proliferation in normal mammary tissue. Ann Med 1998;30:511-24.
8. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-65.
9. Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963-9.
10. Gompel A, Malet C, Spritzer P, Lalardrie JP, Kuttenn F, Mauvais-Jarvis P. Progestin effect on cell proliferation and 17β-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J Clin Endocrinol Metab 1986;63:1174-80.
11. Laidlaw IJ, Clarke RB, Howell A, Owen AW, Potten CS, Anderson E. The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology 1995; 136:164-71.
12. McManus MJ, Welsch CW. The effect of estrogen, progesterone, thyroxine, and human placental lactogen on DNA synthesis of human breast ductal epithelium maintained in athymic nude mice. Cancer 1984;54: 1920-7.
13. Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci U S A 2003;100:9744-9.
14. Huggins C, Moon RC, Morii S. Extinction of experimental mammary cancer. I. Estradiol-17β and progesterone. Proc Natl Acad Sci U S A 1962;48:77-92.
15. Sivaraman L, Medina D. Hormone-induced protection against breast cancer. J Mammary Gland Biol Neoplasia 2002;7:77-92.
16. Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288: 321-33.
17. McGuire WL, Clark GM, Dressier LG, Owens MA. Role of steroid hormone receptors as prognostic factors in primary breast cancer. NCI Monogr 1986;1: 19-23.
18. Brown PH, Lippman SM. Chemoprevention of breast cancer. Breast Cancer Res Treat 2000;62:1-17.
19. Li S, Lepage M, Merand Y, Belanger A, Labrie F. Growth inhibition of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by controlled-release low-dose medroxyprogesterone acetate. Breast Cancer Res Treat 1993;24:127-37.
20. Robinson SP, Jordan VC. Reversal of the antitumor effects of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene-induced rat mammary carcinoma model. Cancer Res 1987;47:5386-90.
21. Lin VC, Eng AS, Hen NE, Ng EH, Chowdhury SH. Effect of progesterone on the invasive properties and tumor growth of progesterone receptor-transfected breast cancer cells MDA-MB-231. Clin Cancer Res 2001;7:2880-6.
22. Michna H, Nishino Y, Neef G, McGuire WL, Schneider MR. Progesterone antagonists: tumor-inhibiting potential and mechanism of action. J Steroid Biochem Mol Biol 1992;41:339-48.
23. Sartorius CA, Groshong SD, Miller LA, et al. New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res 1994;54:3868-77.
24. Graham JD, Yeates C, Balleine RL, et al. Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res 1995;55:5063-8.
25. Bamberger AM, Milde-Langosch K, Schulte HM, Loning T. Progesterone receptor isoforms, PR-B and PR-A, in breast cancer: correlations with clinicopathologic tumor parameters and expression of AP-1 factors. Horm Res 2000;54:32-7.
26. Hopp TA, Weiss HL, Hilsenbeck SG, et al. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 2004;10:2751-60.
27. Keydar I, Chen L, Karby S, et al. Establishment and characterization of a cell line of human breast carcinoma origin. Eur J Cancer 1979;15:659-70.
28. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982;31:11-24.
29. Malzahn K, Mitze M, Thoenes M, Moll R. Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch 1998;433:119-29.
30. van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-6.
31. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004;203:661-71.
32. Sartorius CA, Shen T, Horwitz KB. Progesterone receptors A and B differentially affect the growth of estrogen-dependent human breast tumor xenografts. Breast Cancer Res Treat 2003;79:287-99.
33. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 2002;277:5209-18.
34. McDonnell DP, Goldman ME. RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. J Biol Chem 1994;269: 11945-9.
35. Conneely OM, Lydon JP. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids 2000;65:571-7.
36. Jordan VC, Fritz NF, Langan-Fahey S, Thompson M, Tormey DC. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 1991;83:1488-91.
37. Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989;298:147-51.
38. Saegusa M, Okayasu I. Progesterone therapy for endometrial carcinoma reduces cell proliferation but does not alter apoptosis. Cancer 1998;83:111-21.
39. Focan C, Beauduin M, Salamon E, et al. Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial. Br J Cancer 2001;85:1-8.
40. Pechoux C, Gudjonsson T, Ronnov-Jessen L, Bissell MJ, Petersen OW. Human mammary luminal epithelial cells contain progenitors to myoepithelial cells. Dev Biol 1999;206:88-99.
41. Petersen OW, Nielsen HL, Gudjonsson T, et al. Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am J Pathol 2003;162:391-402.
42. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
43. Behbod F, Rosen JM. Will cancer stem cells provide new therapeutic targets? Carcinogenesis 2004; 30:3-21.
44. Nagle RB. A review of intermediate filament biology and their use in pathologic diagnosis. Mol Biol Rep 1994; 19:3-21.
45. Schaller G, Fuchs I, Pritze W, et al. Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res 1996;2: 1879-85.
46. Bocker W, Moll R, Poremba C, et al. Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept Lab Invest 2002;82:737-46.
47. Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002;82:1525-33.
48. Tran CP, Lin C, Yamashiro J, Reiter RE. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 2002;1:113-21.
49. Otterbach F, Bankfalvi A, Bergner S, Decker T, Krech R, Boecker W. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology 2000;37: 232-40.
50. Trask DK, Band V, Zajchowski DA, Yaswen P, Suh T, Sager R. Keratins as markers that distinguish normal and tumor-derived mammary epithelial cells. Proc Natl Acad Sci U S A 1990;87:2319-23.